Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Indevus/Pliva Co-Promotion Deal Puts 481 Reps Behind Incontinence Drug Sanctura

This article was originally published in The Pink Sheet Daily

Executive Summary

Sanctura (trospium) is currently pending at FDA with a May 28 user fee goal date. Indevus' overactive bladder treatment will face competition from upcoming agents by marketing heavyweights Novartis (Enablex) and GlaxoSmithKline/Yamanouchi (Vesicare); both are "approvable" at FDA.

You may also be interested in...



Pliva Divests Sanctura, Cites Lack Of Resources To Support The Incontinence Agent

The overactive bladder therapy is the first product to be divested as part of a strategic realignment under which Pliva will exit the brand business. The company says brand products are not meeting expectations, and the resources needed are higher than once expected.

Pliva Divests Sanctura, Cites Lack Of Resources To Support The Incontinence Agent

The overactive bladder therapy is the first product to be divested as part of a strategic realignment under which Pliva will exit the brand business. The company says brand products are not meeting expectations, and the resources needed are higher than once expected.

Indevus To Price Sanctura At 10% Discount To Pfizer Detrol LA

A daily dose of Sanctura – two 20 mg tablets – will carry an average wholesale price of $2.98. Retail pharmacies will begin receiving initial shipments of the incontinence agent over the next week, Indevus said.

Topics

UsernamePublicRestriction

Register

PS059324

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel